RxDoctor Payments Data

Robert Block, MD

Internal Medicine · Rochester, NYNPI 1861686685

Payments from drug & device makers

$233,229in general payments, 2019–2025

Across 42 payments — averaging $5553.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$95K
  • Amgen$74K
  • Eli Lilly$41K
  • Akcea Therapeutics, Inc.$10K
  • Ionis Pharmaceuticals, Inc.$8K
  • Regeneron$4K
  • plus $139 from 1 others

What the payments were for

  • Consulting fees$3,60468%
  • Travel & lodging$85616%
  • Food & beverage$79515%
  • Education$561%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis19$95,186
Amgen12$74,336
Eli Lilly3$41,309
Akcea Therapeutics, Inc.1$10,179
Ionis Pharmaceuticals, Inc.3$8,363
Regeneron3$3,718
Esperion Therapeutics, Inc.1$139

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$233,229 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$5,893
Medicare patients
44
Services billed
57

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab466$468,418
Praluent PenAlirocumab250$171,669
VascepaIcosapent Ethyl28$21,367
NexletolBempedoic Acid31$20,448
Ezetimibe357$10,695
Repatha PushtronexEvolocumab11$8,421
Icosapent Ethyl21$7,460
Rosuvastatin Calcium199$3,369
Omega-3 Acid Ethyl Esters15$1,665
Fluvastatin ErFluvastatin Sodium21$1,427
Atorvastatin Calcium70$682
FenofibrateFenofibrate Nanocrystallized26$520
Amlodipine Besylate43$295
Metoprolol Succinate13$179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Esperion Therapeutics, Inc.Nexletol$139$20,44831 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →